On Friday, Catalent stock earned a positive adjustment to its Relative Strength (RS) Rating, from 63 to 74.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's proprietary rating identifies share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks often have an RS Rating of above 80 in the early stages of their moves. See if Catalent stock can continue to show renewed price strength and hit that benchmark.
See How IBD Helps You Make More Money In Stocks
Is Catalent Stock A Buy?
Catalent stock is not currently offering a proper buying opportunity. See if the stock goes on to build a chart pattern that could ignite a new run. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Earnings growth rose last quarter from -52% to -26%. But revenue gains fell from 0% to -6%.
Catalent stock holds the No. 7 rank among its peers in the Medical-Research Equipment/Services industry group. Icon PLC and Natera are also among the group's highest-rated stocks.
